ライフサイエンスコーパス: gynecologic

1 rs) with stage I to IV lung (29%), GI (27%), gynecologic (17%), breast (11%), genitourinary (10%), or

2 Despite similar gynecologic age, body mass index, and type of sports par

3 for orthopedic surgery to 53.8% in urologic/gynecologic and 53.6% in other procedures.

4 HA membrane reduces adhesions in gynecologic and abdominal surgery but this is the first

5 eq data profiling chromatin accessibility in gynecologic and basal breast cancer cell lines and apply

6 and 2012 at an academic medical center with gynecologic and breast cancer centers.

7 ts (all P < .05); significant differences in gynecologic and cancer-specific concerns (P < .05) were

8 gnificantly improved depression and improved gynecologic and cancer-specific concerns at 4 months com

9 Given the unpleasant gynecologic and nongynecologic adverse effects of estrog

10 Estrogen therapy can have unpleasant gynecologic and nongynecologic adverse events.

11 te the association between FGM/C and painful gynecologic and obstetric complications in women affecte

12 oductive tract (FRT) is associated with many gynecologic and obstetric health complications.

13 ned studies reporting prevalences of painful gynecologic and obstetric sequelae resulting from FGM/C.

14 Risks of combined gynecologic and plastic surgical procedures are not grea

15 ant cancer excesses overall, particularly of gynecologic and thyroid cancers.

16 primary site of cancer, including lung, GI, gynecologic, and brain; and comorbidities, including inf

17 ones on the progression of breast, prostate, gynecologic, and colorectal cancer.

18 General surgical, gynecologic, and orthopedic procedures composed 95.8% of

19 Sociodemographic, gynecologic, and periodontal variables were gathered for

20 ic body CT has become invaluable to medical, gynecologic, and radiation oncologists.

21 base, to identify adults undergoing general, gynecologic, and urologic surgical procedures between 20

22 (general surgery, orthopedic, neurosurgical, gynecologic, and urologic) in adult patients with low su

23 ignant ovarian ascites and from nonmalignant gynecologic ascites.

24 ; 95% CI, 0.30 to 1.22) and BRCA2-associated gynecologic cancer (HR = 0.00; 95% CI, not estimable) wa

25 mary diagnosis of breast (stage 0 to III) or gynecologic cancer (International Federation of Gynecolo

26 Ovarian cancer is the second most common gynecologic cancer among women and the second leading ca

27 recruited: breast, prostate, colorectal, and gynecologic cancer and non-Hodgkin's lymphoma.

28 impact when PET is utilized in patients with gynecologic cancer are primarily limited to patients wit

29 t may prove to be a mainstay in personalized gynecologic cancer care.

30 diated metabolic coupling between O-ASCs and gynecologic cancer cells in which O-ASCs support NO home

31 cer Cell Line Encyclopedia databank, 68% are gynecologic cancer cells.

32 controlled trial was undertaken within eight gynecologic cancer centers in the Netherlands.

33 e, US Department of Defense, Sanofi-Aventis, Gynecologic Cancer Foundation, Marcus Foundation, and th

34 Endometrial cancer is the most common gynecologic cancer in the United States and its incidenc

35 Endometrial cancer is the most common female gynecologic cancer in the United States.

36 Cervical cancer is the third most common gynecologic cancer in the United States.

37 Ovarian cancer is the most lethal type of gynecologic cancer in the Western world.

38 ctive in decreasing risks of both breast and gynecologic cancer in women with BRCA mutations.

39 lactic oophorectomy for reducing the risk of gynecologic cancer in women with BRCA1 or BRCA2 mutation

40 We describe RECIST and Gynecologic Cancer InterGroup (GCIG) CA125 responses in

41 randomised, controlled, phase 3, three-arm, Gynecologic Cancer Intergroup (GCIG) trial done at 117 h

42 cer achieved RECISTv1.1 partial response and Gynecologic Cancer Intergroup CA125 response despite bei

43 Secondary end points included response by Gynecologic Cancer Intergroup criteria, duration of ORR,

44 Response was evaluated by RECIST v1.1 and Gynecologic Cancer Intergroup criteria.

45 ial 178 patients (n = 288) and compared with Gynecologic Cancer Intergroup criterion.

46 terval between surgery and chemotherapy, and Gynecologic Cancer InterGroup group.

47 In the Gynecologic Cancer Intergroup International Collaboratio

48 through academic research groups such as the Gynecologic Cancer Intergroup.

49 ic minority, low-income women with breast or gynecologic cancer is prevalent and is correlated with p

50 The omission of DWI for staging or restaging gynecologic cancer may significantly reduce examination

51 for subsequent breast cancer or BRCA-related gynecologic cancer of 0.25 (95 percent confidence interv

52 dity; mortality; diagnostic accuracy for any gynecologic cancer or condition except cervical cancer,

53 er (30% of breast cancer patients and 17% of gynecologic cancer patients).

54 ed with an 85% reduction in BRCA1-associated gynecologic cancer risk (hazard ratio [HR] = 0.15; 95% C

55 ely adopted as a key component of breast and gynecologic cancer risk-reduction for women with BRCA1 a

56 nical guidelines, all young individuals with gynecologic cancer should be counseled about the availab

57 As the number of gynecologic cancer survivors grows, there is an increase

58 ent studies to help the clinician caring for gynecologic cancer survivors in recognizing and treating

59 me to diagnosis of breast or BRCA-associated gynecologic cancer was analyzed using a Cox proportional

60 The time to breast cancer or BRCA-related gynecologic cancer was longer in the salpingo-oophorecto

61 Rates of the most common gynecologic cancer, endometrioid adenocarcinoma (EAC), c

62 % over a lifetime, but it is the most deadly gynecologic cancer, in part due to lack of diagnostic ma

63 ovarian cancer is the most frequent cause of gynecologic cancer-related mortality in women, and progn

64 an cancer is the leading cause of death from gynecologic cancer.

65 among women who are diagnosed with breast or gynecologic cancer.

66 for prevention of breast and BRCA-associated gynecologic cancer.

67 infertility as a sequel to the treatment of gynecologic cancer.

68 Ovarian cancer is the deadliest gynecologic cancer.

69 e the risk of breast cancer and BRCA-related gynecologic cancer.

70 lementary roles in the care of patients with gynecologic cancer.

71 se (254.4 ng/mL), and 47 patients with other gynecologic cancers (260.9 ng/mL).

72 ociated with an increased risk of breast and gynecologic cancers (OR = 4.37, 95% CI: 2.68-7.13, P < 0

73 vity on survival or recurrence in breast and gynecologic cancers are not yet established, and randomi

74 dy to determine the reduction in the risk of gynecologic cancers associated with prophylactic hystere

75 Tumors from patients with advanced stage gynecologic cancers decorated with CD80-SA elicited pote

76 ts of continuous combined hormone therapy on gynecologic cancers have not been investigated previousl

77 ian cancer is the first in mortalities among gynecologic cancers in the United States, often due to l

78 ntinues to carry the highest mortality among gynecologic cancers in the western world.

79 of subsequent breast cancer and BRCA-related gynecologic cancers in women with BRCA mutations.

80 inoma is the most common cause of death from gynecologic cancers largely due to advanced, relapsed an

81 tection conferred by RRSO against breast and gynecologic cancers may differ between carriers of BRCA1

82 PET is used in patients with other gynecologic cancers such as endometrial cancer, uterine

83 The incidence of other gynecologic cancers was low and did not differ by random

84 ctal cancer, retroperitoneal sarcoma, select gynecologic cancers, and other malignancies.

85 could contribute to tumor immune evasion in gynecologic cancers, especially in endometrial cancer.

86 etween cancer behavior and HE4 production in gynecologic cancers, our findings may provide insight us

87 involvement of c-fms and its ligand CSF-1 in gynecologic cancers, such as that of the uterus and the

88 ted and efficacious treatment for women with gynecologic cancers.

89 atment of persistent or recurrent metastatic gynecologic cancers.

90 development of new treatment strategies for gynecologic cancers.

91 and SMAD3 transcription and tumor growth in gynecologic cancers.

92 al activity, or diet with prognosis in other gynecologic cancers.

93 ant means for immunologic targeting of human gynecologic cancers.

94 ses of cervical cancer, and 7 cases of other gynecologic cancers.

95 genomic profiling for precision treatment of gynecologic cancers.

96 patients with advanced endometrial and other gynecologic cancers.

97 s of breast cancer, non-Hodgkin lymphoma, or gynecologic cancers.

98 GMT promoter hypermethylation and breast and gynecologic cancers.

99 of MGMT promoter and the risk of breast and gynecologic cancers.

100 (MGMT) remains controversial for breast and gynecologic cancers.

101 UCSs shared proteomic features with gynecologic carcinomas and sarcomas with intermediate EM

102 Referral should be sought for specialized gynecologic care and for issues related to HIV itself, s

103 ington State women who presented for routine gynecologic care from 1997 to 2001 was conducted.

104 esia developments well applied to ambulatory gynecologic cases.

105 23 to 42 years) was undertaken in a private gynecologic center between weeks 32 and 35 of pregnancy

106 colaou smear, and/or women seeking a routine gynecologic checkup.

107 iated with increased risk of obstetrical and gynecologic complications and acquisition of sexually tr

108 ociated with a wide variety of obstetric and gynecologic complications including serious infections a

109 TC benefits mood and QOL cancer-specific and gynecologic concerns for a multiethnic underserved popul

110 o are not at increased risk for any specific gynecologic condition.

111 ndiceal gastrointestinal conditions (46.0%), gynecologic conditions (21.6%), genitourinary conditions

112 anced-stage EOC from women with nonmalignant gynecologic conditions and may be complementary to CA125

113 independent sera of women with nonmalignant gynecologic conditions and those with advanced-stage or

114 arms of the screening pelvic examination for gynecologic conditions for the US Preventive Services Ta

115 robotically assisted hysterectomy for benign gynecologic conditions has been reported, little is know

116 early detection and treatment of a range of gynecologic conditions in asymptomatic, nonpregnant adul

117 rce (USPSTF) recommendation on screening for gynecologic conditions with pelvic examination for condi

118 Endometriosis is a prevalent gynecologic disease associated with systemic chronic inf

119 d with healthy controls or women with benign gynecologic diseases.

120 14 patients having other benign or malignant gynecologic diseases.

121 robotically assisted hysterectomy for benign gynecologic disorders increased substantially.

122 onography in the diagnosis and management of gynecologic disorders of the pediatric pelvis, including

123 Gynecologic evaluation included Nugent score and Amsel c

124 Gynecologic evaluation included Nugent score assessment,

125 Gynecologic exam revealed a 3-cm barrel-shaped cervix wi

126 nal discharge, STI exposure, or preventative gynecologic examination were evaluated for Trichomonas i

127 e CD4 lymphocyte count, HIV-1 RNA level, and gynecologic examination with Papanicolaou smear.

128 neficial association with patient receipt of gynecologic examinations and Papanicolaou smears, choles

129 Gynecologic examinations and sexual quality-of-life ques

130 g and Papanicolaou testing were collected at gynecologic examinations every four months.

131 Triannual gynecologic examinations included cervical and vulvovagi

132 lum and feelings of vulnerability during the gynecologic exams are two of the biggest barriers to cer

133 Obstetric-gynecologic findings (OR, 4.4; 95% CI: 2.1, 9.6) and acu

134 Patients receiving chemotherapy for lung, gynecologic, genitourinary, or breast cancer at a tertia

135 e reproductive tract of women with obstetric/gynecologic health complications.

136 We integrated data on gynecologic history with levels of an ovarian reserve ma

137 ata and sexual behavior; STI, obstetric, and gynecologic history; and urine, vaginal, endocervical, a

138 arcomas are unusual tumors that are commonly gynecologic in origin, where they are referred to as mal

139 A gynecologic infection is the most common symptom that le

140 1.7, 95% CI: 1.1, 2.6), and prior history of gynecologic infection/disease (OR = 2.6, 95% CI: 1.2, 5.

141 garette smoking, aspirin use, and history of gynecologic infection/disease.

142 Local anesthetic use in gynecologic laparoscopy appears to improve postoperative

143 he highest prevalences were in patients with gynecologic malignancies (two of 13, 15%) and in those w

144 um (HOSE) is the leading cause of death from gynecologic malignancies among American women.

145 an cancer is the leading cause of death from gynecologic malignancies amongst American women.

146 ed to validate the use of robotic surgery in gynecologic malignancies and to compare its outcomes to

147 tion of Gynecology and Obstetrics staging of gynecologic malignancies are also described in detail, h

148 chniques used in evaluation of patients with gynecologic malignancies are described, including both a

149 Eighty patients with gynecologic malignancies beginning standard chemotherapy

150 Current therapy of gynecologic malignancies consists of platinum-containing

151 erous adenocarcinomas of the ovary and other gynecologic malignancies that is distinguished by highly

152 types were similar in both groups, but fewer gynecologic malignancies were noted in GCA patients (OR

153 ET imaging is underutilized in patients with gynecologic malignancies, and its role in current clinic

154 ins the leading cause of death in women with gynecologic malignancies, despite surgical advances and

155 veral treatment modalities are used to treat gynecologic malignancies, including surgery, radiotherap

156 radical procedures and decrease morbidity in gynecologic malignancies, much effort is being focused o

157 osis of ovarian cancer, the deadliest of the gynecologic malignancies, reflects major limitations ass

158 the p53 and BRCA1 tumor suppressor genes in gynecologic malignancies, we generated mice in which p53

159 eatment options and therapy in patients with gynecologic malignancies.

160 l ovarian cancer (EOC) is the most lethal of gynecologic malignancies.

161 g recurrent tumor after treatment of various gynecologic malignancies.

162 e use of robotic surgery in the treatment of gynecologic malignancies.

163 use of robotic surgery in the management of gynecologic malignancies.

164 Ovarian cancer is the most lethal of the gynecologic malignancies.

165 n cancer is the leading cause of death among gynecologic malignancies.

166 the-art use of PET imaging for patients with gynecologic malignancies.

167 e highest mortality rate among patients with gynecologic malignancies.

168 ct management and prognosis of patients with gynecologic malignancies.

169 with excellent survival compared with other gynecologic malignancies.

170 Ovarian cancer is the most lethal gynecologic malignancy and the fifth leading cause of ca

171 Epithelial ovarian cancer is the most lethal gynecologic malignancy and the fifth most common cause o

172 Endometrial cancer is the most common gynecologic malignancy and the fourth most common malign

173 lial ovarian cancer (EOC) is a highly lethal gynecologic malignancy arising from the fallopian tubes

174 Ovarian cancer is a deadly gynecologic malignancy for which novel biomarkers and th

175 Ovarian cancer is the most lethal gynecologic malignancy in both African-American and whit

176 ovarian carcinoma (HGSOC) is the most lethal gynecologic malignancy in industrialized countries and h

177 ade serous ovarian cancer (HGSOC) is a fatal gynecologic malignancy in the U.S. with limited treatmen

178 Endometrial cancer is the most common gynecologic malignancy in the United States and the most

179 ovarian cancer (EOC) remains the most lethal gynecologic malignancy in the United States.

180 Ovarian cancer remains the most lethal gynecologic malignancy in the United States.

181 ndometrial adenocarcinoma is the most common gynecologic malignancy in the United States.

182 n cancer, is the major cause of death due to gynecologic malignancy in the Western world, with chemot

183 Although ovarian cancer is the most lethal gynecologic malignancy in women, little is known about h

184 Gynecologic malignancy is one of the leading causes of m

185 Ovarian cancer is a lethal gynecologic malignancy that may benefit from new therapi

186 Uterine leiomyosarcoma (ULMS) is a rare gynecologic malignancy with a low survival rate.

187 Ovarian cancer is the most lethal gynecologic malignancy with an overall cure rate of mere

188 n and the second leading cause of death from gynecologic malignancy worldwide.

189 Endometrial cancer is the most common gynecologic malignancy, and its incidence and associated

190 Ovarian cancer, the most deadly gynecologic malignancy, is often diagnosed late and at t

191 ovarian cancer (EOC) remains the most lethal gynecologic malignancy, underscoring the need for better

192 cer (EOC) is the leading cause of death from gynecologic malignancy, with high mortality attributable

193 ovarian cancer is the most frequent cause of gynecologic malignancy-related mortality in women.

194 lial ovarian cancer (EOC) is the most lethal gynecologic malignancy.

195 ctor for endometrial cancer, the most common gynecologic malignancy.

196 w incidence rate, it remains the most deadly gynecologic malignancy.

197 Ovarian cancer remains the most lethal gynecologic malignancy.

198 ate the therapeutic potential of SK1 in this gynecologic malignancy.

199 lial ovarian cancer (EOC) is the most lethal gynecologic malignancy.

200 tly needed for ovarian cancer, the deadliest gynecologic malignancy.

201 Epithelial ovarian cancer is the most lethal gynecologic malignancy; it is highly aggressive and caus

202 leiomyomas (fibroids) are a major source of gynecologic morbidity in reproductive age women and are

203 e ovarian serous carcinomas, the most lethal gynecologic neoplastic disease in women.

204 The importance of associated urologic, gynecologic, neurologic, and orthopedic malformations ha

205 030 enrolled patients who underwent general, gynecologic, neurologic, or cardiothoracic surgery, 3864

206 guidelines for optimizing the management of gynecologic/obstetric events in female patients with HAE

207 number of publications on the management of gynecologic/obstetric events in female patients with her

208 lege of Surgeons hospital and treatment by a gynecologic oncologist increased the likelihood of recei

209 lial ovarian cancer should be evaluated by a gynecologic oncologist prior to initiation of therapy.

210 administered by medical oncologists (MOs) or gynecologic oncologists (GOs).

211 Of 18,338 women, 21.4% received care from gynecologic oncologists (group A) while 78.6% were treat

212 necology has recommendations for referral to gynecologic oncologists for the treatment of endometrial

213 Care provided by gynecologic oncologists improved the survival of those w

214 re, we propose to determine the influence of gynecologic oncologists on the treatment and survival of

215 , early stage, lower grade, and treatment by gynecologic oncologists were independent prognostic fact

216 Patients with endometrial cancer treated by gynecologic oncologists were more likely to undergo stag

217 medical oncologists, radiation oncologists, gynecologic oncologists, urologists, hematologists, pedi

218 eated by medical oncologists, urologists, or gynecologic oncologists.

219 The Society of Gynecologic Oncology and the American Society of Clinica

220 went prophylactic surgery in the Division of Gynecologic Oncology at Brigham and Women's Hospital.

221 ness analysis compared the three arms of the Gynecologic Oncology Group (GOG) 218 study (paclitaxel p

222 erim analysis (in 2012) of 271 deaths in the Gynecologic Oncology Group (GOG) 240 trial.

223 In this regard, the Gynecologic Oncology Group (GOG) and other organizations

224 The Gynecologic Oncology Group (GOG) conducted a phase II tr

225 ) gynecologic tissue bank (n = 570) and from Gynecologic Oncology Group (GOG) phase III clinical tria

226 ocyte DNA from women who participated in the Gynecologic Oncology Group (GOG) phase III protocol-172

227 Patients entered on Gynecologic Oncology Group (GOG) Protocol 179 were expec

228 e from women participating in representative Gynecologic Oncology Group (GOG) protocols.

229 A Gynecologic Oncology Group (GOG) randomized phase III tr

230 5 patients with EOC or PPC enrolled onto the Gynecologic Oncology Group 182 study.

231 randomized phase III intergroup trial of the Gynecologic Oncology Group and National Cancer Institute

232 The Gynecologic Oncology Group conducted a phase II evaluati

233 The Gynecologic Oncology Group conducted a randomized, phase

234 ted for response and toxicity using standard Gynecologic Oncology Group criteria.

235 College of Radiology Imaging Network and the Gynecologic Oncology Group from March 2000 to November 2

236 mber 2011, 55 patients were enrolled by five Gynecologic Oncology Group member institutions; of those

237 the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group neurotoxicity questionnaire a

238 The Functional Assessment of Cancer Therapy/Gynecologic Oncology Group neurotoxicity questionnaire w

239 Inclusion criteria included a Gynecologic Oncology Group performance status of 0 to 2

240 cytotoxic regimens, measurable disease, and Gynecologic Oncology Group performance status of at leas

241 merican College of Radiology Imaging Network/Gynecologic Oncology Group prospective clinical trial wa

242 an cancer specimens from patients treated on Gynecologic Oncology Group protocol 111.

243 analyzed surgical treatment arm results from Gynecologic Oncology Group Protocol-0199 (GOG-0199), the

244 Data from Gynecologic Oncology Group protocols 114 and 172 were re

245 tumors from 125 patients participating in a Gynecologic Oncology Group randomized phase III treatmen

246 can College of Radiology Imaging Network and Gynecologic Oncology Group study of 172 women with biops

247 ve Ovarian Neoplasm Group trial (ICON7), the Gynecologic Oncology Group trial (GOG218), OCEANS and AU

248 ested on Southwest Oncology Group trial 9701/Gynecologic Oncology Group trial 178 patients (n = 288)

249 unctional Assessment of Cancer Therapy Scale/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx)

250 rted Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity four-item senso

251 the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity, may be used in

252 omized phase III trial conducted through the Gynecologic Oncology Group.

253 The Society of Gynecologic Oncology guidelines categorize CA-125 testin

254 , the University of California San Francisco Gynecologic Oncology Program instituted a surgical-patho

255 enior nuclear medicine specialist in PET for gynecologic oncology reviewed all (18)F-FDG PET/CT scans

256 al criteria (Amsterdam, Bethesda, Society of Gynecologic Oncology, ANECS).

257 iology, obstetric, interventional radiology, gynecologic oncology, blood bank, and specialized surgic

258 ined a strong foothold in urologic oncology, gynecologic oncology, cardiothoracic surgery and now in

259 y convened a Panel of experts in medical and gynecologic oncology, clinical pharmacology, pharmacokin

260 ternational experts in genetics, medical and gynecologic oncology, clinical psychology, epidemiology,

261 In current gynecologic oncology, HIFU is used clinically in the tre

262 of prospective trials validating its use in gynecologic oncology.

263 (12.1%), lymph nodes (10.9%), breast (7.6%), gynecologic organs (7.1%), genitourinary organs (4.2%),

264 ancies, and 27 with benign lesions involving gynecologic organs.

265 the prevention of breast and BRCA-associated gynecologic (ovarian, fallopian tube or primary peritone

266 time risk of both breast and BRCA-associated gynecologic (ovarian, fallopian tube, and primary perito

267 All cases were reviewed by a gynecologic pathologist, and clinical information was ab

268 icians and Gynecologists (ACOG) Committee on Gynecologic Practice had previously issued a committee o

269 al of the IUD, or the presence or absence of gynecologic problems related to its use.

270 used extensively in the evaluation of common gynecologic problems, such as menorrhagia and postmenopa

271 All patients undergoing gastrointestinal or gynecologic procedures from January 1, 2005 to June 1, 2

272 Several gynecologic procedures including tubal ligation, oophore

273 ding colorectal, arthroplasty, vascular, and gynecologic procedures.

274 , 5 to 67 ng/mL) for individuals with benign gynecologic processes (P = NS).

275 gh-risk individuals, 33 patients with benign gynecologic processes, and 50 preoperative patients subs

276 ribution to the banked clinical successes in gynecologic radiation oncology.

277 RECENT FINDINGS: Small-cell carcinomas of gynecologic sites are rare and carry a poor prognosis.

278 erican Medical Association, and the American Gynecologic Society.

279 e with good performance status presented for gynecologic surgery for a benign condition.

280 The benefit of prophylactic gynecologic surgery for women with this syndrome has bee

281 esia care for patients undergoing ambulatory gynecologic surgery has improved incrementally over the

282 ndication undergoing general, orthopedic, or gynecologic surgery were followed for the occurrence of

283 tatus was determined from menstrual history, gynecologic surgery, hormone replacement therapy, follic

284 vascular surgery, and 10.7% (36 of 336) for gynecologic surgery.

285 Although there is some increase in gynecologic symptoms and diminution in sexual pleasure,

286 the strongest effects on physical health and gynecologic symptoms followed similar patterns.

287 62; 95% CI, 0.42 to 0.91; P = .016), whereas gynecologic symptoms were significant only in the tamoxi

288 ified from the University of Washington (UW) gynecologic tissue bank (n = 570) and from Gynecologic O

289 POSE OF REVIEW: Small-cell carcinomas of the gynecologic tract are aggressive malignancies that can b

290 The majority of small-cell tumors of the gynecologic tract will require systemic chemotherapy wit

291 sensitivities based on subcategorization of gynecologic tumors and identify TP53 mutation as a molec

292 nd 50 JAK1 truncating mutations in 36 of 635 gynecologic tumors in the Total Cancer Care(R) (TCC(R))

293 ard this goal, we establish a library of 139 gynecologic tumors including epithelial ovarian cancers

294 rols with a differential diagnosis of benign gynecologic tumors, and 10 diseased epithelial ovarian c

295 rian cancer has the highest mortality of all gynecologic tumors, and there is an urgent need for spec

296 er as it is the leading cause of death among gynecologic tumors.

297 umorigenesis, progression, and metastasis of gynecologic tumors.

298 Excluding procedures for gynecologic/urologic malignancies, the proportion of pro

299 accounts for a significant proportion of all gynecologic visits in the United States.

300 oups (17 general surgical, 6 vascular, and 1 gynecologic) were examined.